Innovative OncoSignal technology enables rapid measurement of key oncogenic signaling pathways for targeted breast cancer treatment
ORLANDO, FL / ACCESSWIRE / April 12, 2021 / Protean BioDiagnostics Inc. ("Protean"), a disruptive biotechnology company developing and commercializing novel cancer diagnostics supporting precision oncology, today announced that Dr. Anthony Magliocco, President and CEO of Protean, presented a poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held April 10-15 and May 17-21, 2021.
"The proprietary and novel OncoSignal assay can accurately quantify the extent of specific and therapy targetable pathway activation in breast cancer and other cancer tissues using a rapid, modified transcriptome analysis approach," said Dr. Anthony Magliocco, President and CEO of Protean. "Significantly, the method can be applied to routinely collected pathology specimens. It may also overcome limitations in next generation sequencing where changes of uncertain significance are commonly detected."
The poster (#533), titled: "Breast Cancer IHC Subtypes Display Heterogeneous And Independent Targetable Signaling Pathway Activity Profiles", reviews data that may provide a superior approach to current immunohistochemistry (IHC) methods to more effectively and rapidly select breast cancer patients for targeted therapy treatments.
The poster presentation features key observations including:
- The OncoSignal assay can accurately measure the activity of key targetable molecular driver signal pathways in breast cancer
- OncoSignal estrogen receptor pathway activity scores (PAS) are strongly associated with luminal A, B, HER2 and triple negative breast cancer subtypes as defined by routine IHC
- OncoSignal can measure PAS in key targetable pathways including MAPK, androgen receptor, and PI3K and may enable the identification of individual tumors where these pathways are the dominant oncogenic drivers and attractive therapeutic targets
Each breast cancer subtype based on IHC, had in the overall population a typical pathway activity profile. However, within each IHC subtype, a substantial range of pathway activities between patients was observed, suggesting that within same IHC subtypes, clear differences in signal pathway activation can be measured that may provide a novel approach to more effectively select patients for specific precision oncology targeted therapy treatments.
Protean BioDiagnostics has developed a proprietary Precision Medicine system "Oncology MAPS" which includes advanced diagnostic methods including OncoSignal technology to assist physicians with treatment selection for their cancer patients.
About Protean BioDiagnostics Inc.
Protean BioDiagnostics is a disruptive biotechnology company developing and commercializing novel cancer diagnostics supporting precision oncology. Protean has created Oncology MAPS™ - a unique and innovative, fully integrated diagnostic system for oncologists. This easy-to-deploy system enables rapid access to precision diagnostics for underserved community-based cancer doctors and their patients wherever they practice. Oncology MAPS includes comprehensive support and access to the latest genetic, molecular and cancer blood monitoring tests as well as educational and telemedicine support.
Protean is transforming cancer practice using a big data approach which integrates digital pathology, multi-omics, and artificial intelligence. Protean also provides support for contract research, clinical trials, and novel biomarker development using its CAP-accredited, CLIA-certified laboratories and through its extensive client networks.
Companion diagnostics can be quickly evaluated and deployed leveraging Protean's extensive laboratory capabilities, expertise, and extensive global research networks.
CONTACT:
Paul Moon
Paul.moon@proteanbiodx.com
403-390-1676
SOURCE: Protean BioDiagnostics
View source version on accesswire.com:
https://www.accesswire.com/639789/Protean-BioDiagnostics-Presents-Poster-at-AACR-2021-Annual-Meeting
